N-glycan biosignatures as a potential diagnostic biomarker for early-stage pancreatic cancer

doi:10.4251/wjgo.v16.i3.659

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 3

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2082)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-5) series, Tables (1-5) series.

Item

Count

PDF

WORD

HTML

1141

Figures (1-5)

152

Tables (1-5)

190

Sum=1543

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

101

Download

340

Sum=441

Mar 15, 2024 (publication date) through Jan 19, 2025

Times Cited of This Article

Times Cited (1)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Control Study

World J Gastrointest Oncol. Mar 15, 2024; 16(3): 659-669
Published online Mar 15, 2024. doi: 10.4251/wjgo.v16.i3.659

Table 5 The positivity rate of Glyco-model among patients with pancreatic ductal adenocarcinoma with tumor markers-negative

Tumor marker negative	Glyco-model positivity rate
CEA ≤ 5 (72)	87.50% (63/72)
CA19-9 ≤ 37 (41)	82.93% (34/41)
CA125 ≤ 35 (63)	88.89% (56/63)
CA242 ≤ 30 (65)	83.08% (54/65)
CA724 ≤ 6.9 (74)	86.49% (64/74)

CEA: Carcinoembryonic antigen; CA19-9: Cancer antigen 19-9.

Citation: Wen YR, Lin XW, Zhou YW, Xu L, Zhang JL, Chen CY, He J. N-glycan biosignatures as a potential diagnostic biomarker for early-stage pancreatic cancer. World J Gastrointest Oncol 2024; 16(3): 659-669
URL: https://www.wjgnet.com/1948-5204/full/v16/i3/659.htm
DOI: https://dx.doi.org/10.4251/wjgo.v16.i3.659